Silvercrest Asset Management’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.02M | Hold |
54,723
| – | – | 0.02% | 492 |
|
|
2025
Q1 | $2.65M | Sell |
54,723
-29,703
| -35% | -$1.44M | 0.02% | 503 |
|
|
2024
Q4 | $3.26M | Sell |
84,426
-828
| -1% | -$32K | 0.02% | 470 |
|
|
2024
Q3 | $3.84M | Sell |
85,254
-105,914
| -55% | -$4.77M | 0.03% | 410 |
|
|
2024
Q2 | $6.62M | Buy |
191,168
+2,425
| +1% | +$84K | 0.05% | 350 |
|
|
2024
Q1 | $5.46M | Buy |
188,743
+8,247
| +5% | +$239K | 0.04% | 377 |
|
|
2023
Q4 | $4.14M | Buy |
180,496
+34
| +0% | +$780 | 0.03% | 403 |
|
|
2023
Q3 | $3.01M | Buy |
180,462
+52,265
| +41% | +$872K | 0.02% | 431 |
|
|
2023
Q2 | $3.54M | Buy |
128,197
+14,842
| +13% | +$410K | 0.03% | 417 |
|
|
2023
Q1 | $2.61M | Sell |
113,355
-127,390
| -53% | -$2.93M | 0.02% | 441 |
|
|
2022
Q4 | $2.63M | Sell |
240,745
-2,268
| -0.9% | -$24.7K | 0.02% | 431 |
|
|
2022
Q3 | $2.05M | Buy |
243,013
+128,254
| +112% | +$1.08M | 0.02% | 441 |
|
|
2022
Q2 | $908K | Sell |
114,759
-5,075
| -4% | -$40.2K | 0.01% | 580 |
|
|
2022
Q1 | $2.84M | Buy |
119,834
+1,119
| +0.9% | +$26.5K | 0.02% | 449 |
|
|
2021
Q4 | $4.06M | Buy |
118,715
+47,372
| +66% | +$1.62M | 0.03% | 411 |
|
|
2021
Q3 | $1.26M | Sell |
71,343
-48,048
| -40% | -$851K | 0.01% | 539 |
|
|
2021
Q2 | $5.36M | Buy |
+119,391
| New | +$5.36M | 0.04% | 379 |
|